Reta Glp 3 (Retatrutide) 30mg Research Peptide
Retatrutide is a triple receptor agonist (GLP-1R, GIPR, GCGR) peptide developed by Eli Lilly. This 30mg vial provides research-grade retatrutide at ≥99% purity for in vitro research applications requiring bulk quantity. HPLC and MS/MS verified per batch.
Research Background
Published Phase 2 data (NEJM, 2023) showed retatrutide achieving up to 24.2% body weight reduction over 48 weeks and significant hepatic fat reduction, supporting research into obesity, NAFLD/MASH, and insulin resistance models. The compound’s GCGR component raises basal energy expenditure and promotes hepatic fat clearance. Phase 3 TRIUMPH trials ongoing as of 2026.
For a full overview of retatrutide’s mechanism, clinical trial data, dosage reference, and comparison with tirzepatide, see our Retatrutide Peptide Research Guide. Also available in 10mg, 20mg, and 40mg vials.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 30mg per vial
- Storage: −20°C, protected from light
- CAS Number: 2381272-12-2
Certificate of Analysis
Third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
